{"id":10323,"date":"2025-06-24T09:01:11","date_gmt":"2025-06-24T09:01:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/10323\/"},"modified":"2025-06-24T09:01:11","modified_gmt":"2025-06-24T09:01:11","slug":"breyer-capitals-morgan-cheatham-on-investing-in-health-tech","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/10323\/","title":{"rendered":"Breyer Capital’s Morgan Cheatham on investing in health tech"},"content":{"rendered":"

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech\u2019s promise. He\u2019s also the co-author of the free, twice weekly STAT Health Tech newsletter<\/a>. You can reach Mario on Signal at mariojoze.13.<\/p>\n

In April, investor Morgan Cheatham was granted access to a significant fortune and told to go find the next transformational ideas in health care and life sciences. Now, he\u2019s sharing a little more about what exactly he\u2019ll do with it.\u00a0<\/p>\n

Cheatham is the new head of health care and life sciences at Breyer Capital, the investment office of Jim Breyer, who is known for savvy early investments in companies like Facebook and Etsy. Breyer\u2019s health care portfolio includes highly valued companies like Lyra Health and OpenEvidence.\u00a0<\/p>\n

At 29, Cheatham is no slouch himself. In his previous job at Bessemer Venture Partners, he worked on investments for two of the most prominent companies in digital health: Hinge Health, the virtual physical therapy company that went public last month<\/a>, and Abridge, the booming ambient scribing company. In May, he completed his medical degree at Brown University, and in June, began a combined pediatrics and genetics residency program at Boston Children\u2019s Hospital and Harvard. Cheatham has also become a leading advocate for health artificial intelligence and works with both the New England Journal of Medicine AI and the Coalition for Health AI.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 and get additional analysis of the technologies disrupting health care \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…\n","protected":false},"author":3,"featured_media":10324,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[738,210,1141,1142,1595,154,67,132,68],"class_list":{"0":"post-10323","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-artificial-intelligence","9":"tag-health","10":"tag-health-care","11":"tag-healthcare","12":"tag-startups","13":"tag-stat","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114737531115353091","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/10323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=10323"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/10323\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/10324"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=10323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=10323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=10323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}